Ariad Reaches New 52-Week High (ARIA)

NEW YORK ( TheStreet) -- Ariad Pharmaceuticals (Nasdaq: ARIA) hit a new 52-week high Monday as it is currently trading at $16.29, above its previous 52-week high of $15.98 with 435,987 shares traded as of 9:45 a.m. ET. Average volume has been 3.2 million shares over the past 30 days.

Ariad has a market cap of $2.29 billion and is part of the health care sector and drugs industry. Shares are up 28.3% year to date as of the close of trading on Friday.

ARIAD Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small-molecule drugs for the treatment of cancer.

TheStreet Ratings rates Ariad as a hold. The company's strengths can be seen in multiple areas, such as its solid stock price performance and largely solid financial position with reasonable debt levels by most measures. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company's earnings per share, deteriorating net income and disappointing return on equity. You can view the full Ariad Ratings Report.

See all 52-week high stocks or get investment ideas from our investment research center.